Regulation of epithelial-mesenchymal transition by protein lysine acetylation

Fanyun Kong¹, Lihong Ma¹, Xing Wang¹, Hongjuan You¹*, Kuiyang Zheng¹,² and Renxian Tang¹,²*

Abstract

The epithelial-mesenchymal transition (EMT) is a vital driver of tumor progression. It is a well-known and complex trans-differentiation process in which epithelial cells undergo morphogenetic changes with loss of apical-basal polarity, but acquire spindle-shaped mesenchymal phenotypes. Lysine acetylation is a type of protein modification that favors reversibly altering the structure and function of target molecules via the modulation of lysine acetyltransferases (KATs), as well as lysine deacetylases (KDACs). To date, research has found that histones and non-histone proteins can be acetylated to facilitate EMT. Interestingly, histone acetylation is a type of epigenetic regulation that is capable of modulating the acetylation levels of distinct histones at the promoters of EMT-related markers, EMT-inducing transcription factors (EMT-TFs), and EMT-related long non-coding RNAs to control EMT. However, non-histone acetylation is a post-translational modification, and its effect on EMT mainly relies on modulating the acetylation of EMT marker proteins, EMT-TFs, and EMT-related signal transduction molecules. In addition, several inhibitors against KATs and KDACs have been developed, some of which can suppress the development of different cancers by targeting EMT. In this review, we discuss the complex biological roles and molecular mechanisms underlying histone acetylation and non-histone protein acetylation in the control of EMT, highlighting lysine acetylation as potential strategy for the treatment of cancer through the regulation of EMT.

Keywords: Epithelial-mesenchymal transition, Lysine acetylation, Histone, Non-histone protein, Therapy

Background

The epithelial-mesenchymal transition (EMT) is a well-known, complex, reversible cellular trans-differentiation process. During EMT, epithelial cells are not only capable of reorganizing the cytoskeleton and losing cell-cell contacts, but also gain a mesenchymal phenotype to facilitate cell motility, resistance to apoptosis, and ECM production [1, 2]. A strong association between EMT and embryonic organ development, tissue fibrosis, wound healing, and the progression of various cancers has been reported [3, 4]. EMT can regulate tumor migration, chemotherapeutic resistance, metastasis, and the acquisition of stem cell-like characteristics [1, 4]. Moreover, when epithelial cells undergo EMT, the expression of epithelioid markers, including E-cadherin, claudin-1, and EpCAM, is repressed. In contrast, mesenchymal markers, such as N-cadherin, αSMA, and vimentin, are upregulated during this transition [4–7]. In addition, current evidence shows that EMT is a stepwise complex process with distinct intermediate states rather than functioning in a binary manner [8, 9]. In particular, preclinical and clinical observations have demonstrated that some cancer cells undergoing EMT only exhibit partial EMT or a hybrid epithelial/mesenchymal (E/M) state combining both epithelial and mesenchymal phenotype [10–12]. Therefore, further clarification of the hybrid E/M status of different tumors with EMT and the associated molecular mechanisms is needed to provide promising
biomarkers for the diagnosis, prognosis, and treatment of various cancers [10].

Similar to many other biological programs, EMT is controlled by a series of EMT-inducing transcription factors (EMT-TFs), in particular by three main families of EMT-TFs, namely Snail (Snail1/Snail and Sanil2/Slug), Twist (Twist1 and Twist2), and ZEB (ZEB1 and ZEB2), to orchestrate gene expression, including the restriction of epithelial genes and sensitization of mesenchymal genes [13]. In addition, many signaling pathways, including JAK/STAT, NF-κB, TGF-β/Smad, and PI3-K have been demonstrated to be essential for the induction of EMT [4, 14]. More importantly, computational and experimental evidence shows that different types of epigenetic modulation, depending on chromatin alterations [15, 16], DNA methylation, histone modifications [17], and non-coding RNA [18–20], play a vital role in modulating the expression levels of EMT-associated genes by regulating chromatin accessibility, transcription factor activity, and the promoter status of target genes. In addition, post-translational modifications (PTMs), including ubiquitylation, phosphorylation, and sumoylation, can also control EMT by adjusting protein stability, intracellular localization, protein structure, and the function of EMT-related molecules [21].

Lysine acetylation, a conserved protein modification, can transfer an acetyl group from acetyl-coenzyme A to lysine residues on target molecules to change their structures and biological functions [22]. Although acetylation was first discovered in histones 50 years ago [23], advances in proteomics in the last decade have indicated that non-histone proteins can also be acetylated [24]. Importantly, the acetylation or deacetylation levels in most of the identified histone and non-histone proteins result from the balance of opposing enzymatic activities between lysine acetyltransferases (KATs, also called histone acetyltransferases, HATs) and lysine deacetylases (KDACs, also called histone deacetylases, HDACs). Mammalian KATs are divided into nuclear and cytoplasmic KATs, according to their cellular localization. Nuclear KATs are classified into five families based on sequence similarities, including basal transcription factors, GCN5/PACAF, MYST, CBP/p300, and the nuclear receptor coactivator family. However, only a few cytoplasmic KATs have been identified, including KAT1 and TAT1. In addition, KDACs are divided into four classes: class I (HDAC1-3, 8) [22], class II (HDAC4-6, HDAC9-10) [23], class III sirtuins (SIRT1-7) [24], and class IV (HDAC11) [25, 26]. The effects of acetylation on histones and non-histone proteins vary in various biological processes. In particular, histone acetylation is linked to the control of target gene transcription [22], while non-histone protein acetylation contributes to the modulation of enzymatic activity, protein stability, and subcellular localization [24]. Moreover, accumulating evidence has demonstrated that the acetylation of histones and non-histone proteins is essential for EMT.

In this review, we discuss evidence on the biological role and molecular mechanisms associated with both histone and non-histone protein acetylation to control EMT and the potential of targeting protein acetylation to inhibit EMT, which is beneficial for cancer treatment.

**Contribution of histone acetylation to EMT regulation**

Epigenetics mostly regulates all biochemical processes by alternating the genome without changing the nucleotide sequence [18]. To date, different epigenetic changes mediated by non-coding RNAs, DNA methylation, and histone modifications have been identified in the process of EMT [18, 27]. Although the current evidence shows that DNA methylation and histone modification can influence the transcription of target genes, the non-coding RNAs have the capability of regulating the expression of target genes at the post-transcriptional level [15–20], our information regarding epigenetic gene regulation still remains limited. Recent studies have shown that epigenetic molecules can be used for the diagnosis, prediction of prognosis, and therapy response in cancer patients [18]. In addition, understanding the mechanisms responsible for epigenetics-mediated EMT is vital for the discovery of novel strategies to prevent EMT-related cancer progression. Histone acetylation, as a type of epigenetic modification, has a prominent effect on the opening of chromatin assembly and activation of target gene transcription. However, histone deacetylation plays the opposite role [22, 23]. In particular, many studies have revealed that acetylation of distinct histones, including histone 2 (H2) [28, 29], histone 3 (H3) [30, 31], and histone 4 (H4) [32], at the promoter regions of certain genes, is crucial for the regulation of EMT. EMT marker genes, EMT-TFs, and EMT-related long non-coding RNAs (lncRNAs) mediated by histone acetylation have been reported to benefit EMT (Table 1).

**Histone acetylation in modulating the promoters of EMT marker genes**

During EMT, different cancer cells undergo complicated morphogenetic changes with a decrease in epithelial markers, including E-cadherin and EpCAM [3, 7]. In particular, evidence shows that the modulation of histone acetylation at the promoters of E-cadherin and EpCAM stimulated by multiple cellular factors participates in the control of the expression of these two molecules to facilitate EMT. According to the results of chromatin immunoprecipitation (ChIP) assays, miR-N5 decreases CBP, a component of KATs, and mediates H3K56 deacetylation.
Table 1 The information on histone acetylation to regulate EMT-related factors

| Target molecule | Molecular type          | The expression levels of target molecules during EMT | The regulator of target molecule | Histone modifier | Acetylation sites | Target cells                | References |
|-----------------|-------------------------|-----------------------------------------------------|---------------------------------|------------------|------------------|------------------------|------------|
| E-cadherin      | EMT-related epithelioid marker | Down                                                | miR-N5                          | CBP              | H3K56            | Prostate cancer cells  | [33]       |
| E-cadherin      | EMT-related epithelioid marker | Down                                                | SIRT1                           | SIRT1            | H4K16            | Prostate cancer cells  | [34]       |
| E-cadherin      | EMT-related epithelioid marker | Down                                                | Snail1                          | HDAC1, HDAC2     | H3, H4           | Kidney cells           | [35]       |
| E-cadherin      | EMT-related epithelioid marker | Down                                                | Snail2                          | HADC1, HADC2, HADC3 | H3K4, H3K56     | Lung carcinoma cells   | [36]       |
| E-cadherin      | EMT-related epithelioid marker | Down                                                | ZEB1                            | HDAC1, HDAC2     | H3, H4           | Pancreatic cancer cells| [37]       |
| EpCAM           | EMT-related epithelioid marker | Down                                                | ZEB1                            | unknown          | H3K9, H3K27, H4 | Lung cancer cells      | [38]       |
| E-cadherin      | EMT-related epithelioid marker | Down                                                | CPEΔN                           | HDAC1, HDAC3     | H3K9             | Lung cancer cells      | [39]       |
| E-cadherin      | EMT-related epithelioid marker | Down                                                | TRIM28                          | unknown          | H3K9             | Lung cancer cells      | [40]       |
| E-cadherin      | EMT-related epithelioid marker | Down                                                | HOATAIR                         | CBP              | H3K27            | Gastric cancer cells   | [41]       |
| αSMA            | EMT-related mesenchymal marker | Up                                                  | TGF-β1                          | unknown          | H3K27            | Kidney cells           | [42]       |
| αSMA            | EMT-related mesenchymal marker | Up                                                  | Ajuba, Twist1                   | CBP              | H3               | Colorectal cancer cells| [43]       |
| N-cadherin      | EMT-related mesenchymal marker | Up                                                  | unknown                         | unknown          | unknown          | Prostate cancer cells  | [44]       |
| vimentin        | EMT-related mesenchymal marker | Up                                                  | DOT1L                           | P300             | H3               | Breast cancer cells    | [45]       |
| Snail1          | EMT-TF                   | Up                                                  | SND1                            | GCN5, P300,      | H3K9, H3K14,     | Ovarian cancer cells   | [46]       |
| Snail2          | EMT-TF                   | Up                                                  | KLF10                           | HDAC1            | H3K9, H3K27     | Lung adenocarcinoma cells| [47]       |
| Snail2          | EMT-TF                   | Up                                                  | TGF-β                           | HDAC1, HDAC3     | H3K56, H3K4     | HCC cells              | [48]       |
| Snail2          | EMT-TF                   | Up                                                  | LncRNA RP11-367G18.1            | unknown          | H3K27            | In head and neck cancer cells | [49]       |
| Twist 1         | EMT-TF                   | Up                                                  | HAUSP, HIF-1a                   | unknown          | H3K56 a          | Multiple cancer cells  | [50]       |
| Twist 1         | EMT-TF                   | Up                                                  | Wnt/β-catenin, PI3-K signalings | unknown          | H3K27            | Gastric cancer cells   | [51]       |
| Twist 1         | EMT-TF                   | Up                                                  | LncRNA RP11-367G18.1            | unknown          | H4K16            | In head and neck cancer cells | [52]       |
| Twist2          | EMT-TF                   | Up                                                  | ACOT12                          | GCN5             | H3               | HCC cells              | [53]       |
| ZEB1            | EMT-TF                   | Up                                                  | MEF2D                           | P300             | H3                | Colorectal cancer cells| [54]       |
| ZEB2            | EMT-TF                   | Up                                                  | unknown                         | unknown          | H3               | Prostate cancer cells  | [55]       |
| ZEB1            | EMT-TF                   | Up                                                  | DOT1L                           | P300             | H3               | Breast cancer cells    | [46]       |
| ZEB2            | EMT-TF                   | Up                                                  | DOT1L                           | P300             | H3               | Breast cancer cells    | [46]       |
at the promoter of E-cadherin to suppress its expression in prostate cancer [33]. Based on ChiP-coupled quantitative polymerase chain reaction (ChiP-qPCR) experiments, SIRT1, a component of KDACs, was found to induce the deacetylation of H4K16, which is essential for E-cadherin silencing to facilitate EMT in prostate cancer cells [34].

As two core EMT-TFs, Snail1 and Snail2 are often upregulated and have the capability of inhibiting the expression of E-cadherin through a variety of molecular mechanisms, including histone acetylation, to facilitate cancer progression. It is worth noting that Snail1 can bind to the promoter of E-cadherin to trigger chromatin changes with a loss of H3/H4 acetylation at its promoter and downregulate the expression of the E-cadherin gene. Mechanistically, based on ChIP and co-immunoprecipitation (Co-IP) assays, Snail1 has been shown to interact with and recruit two members of HADCs, HDAC1 and HDAC2, to the E-cadherin promoter to facilitate H3 and H4 deacetylation in kidney cells [35]. In addition to Snail1, the inhibition of E-cadherin mediated by Snail2 has been observed to be related to the deacetylation of both H3K4 and H3K56 at the promoter of E-cadherin in lung carcinoma cells [36]. HADC1, HADC2, and HADC3 was found to interact with Snail2 and participate in the regulation of histone acetylation at the E-cadherin promoter. ZEB1, another well-known EMT-TF, recruits HDAC1 and HDAC2, as determined by ChIP and Co-IP assays, to the promoter of E-cadherin to inhibit H3 and H4 acetylation and then downregulate its expression in pancreatic cancer cells [37]. ZEB1 also induces downregulation of EpCAM. In particular, following ZEB1 regulation, the acetylation levels of H3K9, H3K27, and H4 are decreased at the EpCAM promoter, as detected by ChIP experiments, and these reduced histone acetylation have a predominant role in EpCAM inhibition in lung cancer cells [38]. However, the KATs responsible for histone acetylation regulated by ZEB1 to control EpCAM have yet to be fully elucidated.

In addition, the N-terminal-truncated carboxypeptidase E (CPEΔN) protein is a crucial regulator of lung cancer metastasis. Sun et al. showed that CPEΔN accelerated EMT in lung cancer cells. Mechanistically, the CPEΔN protein can cause a reduction in histone H3K9 acetylation at the E-cadherin promoter, which was examined by ChIP assay to block its transcription [39]. HDAC1 and HDAC3 maybe participate in the regulation of histone H3K9 acetylation mediated by CPEΔN. Chen et al. showed that TRIM28 is implicated in TGF-β-stimulated EMT. E-cadherin was upregulated, while Snail1, Snail2, and Twist1 were decreased in TRIM28 knockdown cells. Moreover, elevated deacetylation of H3K9 mediated by TRIM28 is related to the decline of E-cadherin in lung cancer cells [40]. Until now, the molecular mechanisms that contribute to the modulation of histone acetylation at the E-cadherin promoter mediated by TRIM28 have not been fully elucidated, and are worth exploring in the future.

LncRNAs are non-coding RNAs of > 200 bp. Evidence shows that lncRNAs play crucial regulatory roles in EMT in various human cancers. As an important lncRNA, HOX transcript antisense intergenic RNA (HOTAIR) contributes to the development of multiple cancers. In particular, Song et al. showed that, based on the UCSC Genome Browser and ChIP assay, HOTAIR is found to facilitate the decrease in histone H3K27 acetylation at the E-cadherin promoter to inhibit its expression and promote EMT in gastric cancer cells. In addition, decreased histone H3K27, mediated by HOTAIR, has been closely correlated with CBP inhibition (Table 1) [41]. In addition to HOTAIR, whether other lncRNAs participate in the modulation

| Target molecule | Molecular type | The expression levels of target molecules during EMT | The regulator of target molecule | Histone modifier | Acetylation sites | Target cells | References |
|-----------------|---------------|----------------------------------------------------|---------------------------------|-----------------|-----------------|-------------|-----------|
| GHET1           | EMT-related LncRNA | Up | unknown | unknown | H3K27 | HCC cells | [56] |
| ROR             | EMT-related LncRNA | Up | CBP | CBP | H3K27 | Retinoblastoma cells | [57] |
| TINCR           | EMT-related LncRNA | Up | CBP | CBP | H3K27 | Breast cancer cells | [58] |
| PLAC2           | EMT-related LncRNA | Up | CBP | CBP | H3K27 | Oral squamous cell carcinoma cells | [59] |
| ANCR            | EMT-related LncRNA | Up | HDAC3 | HDAC3 | H3, H4 | HCC cells | [32] |
of histone acetylation to regulate E-cadherin expression is unknown. Furthermore, although factors, such as EMT-TFs, CPEΔN, and IncRNA, as mentioned above, facilitate the inhibition of E-cadherin based on the modulation of histone acetylation, whether these factors affect histone acetylation at the promoters of other EMT epithelioid markers is not elaborated and requires further investigation.

Moreover, accumulating evidence has demonstrated that EMT is also related to elevated histone acetylation at the promoters of EMT-related mesenchymal markers, including αSMA, N-cadherin, and vimentin, to facilitate their upregulation in cancers. A recent study showed that the increased acetylation of histone H4 at the αSMA promoter is associated with EMT stimulated by TGF-β2, as detected by the ChIP assay in lens epithelial cells [42]. In addition, TGF-β1 stimulation also increases the recruitment of acetylated H3K27 to the promoters of α-SMA in kidney cells [43].

Twist1 is a core EMT transcription factor that contributes to the transcription of N-cadherin, an EMT-related mesenchymal marker. Relying on Co-IP and ChIP experiments, Wu et al. showed that Ajuba, a multiple LIM domain-containing protein, can recruit CBP as well as Twist1 to form a protein complex at the Twist1-binding region and enhance the acetylation of histone H3 at the N-cadherin promoter in colorectal cancer cells [44]. In addition, increased acetylation of histone H3 in the vimentin promoter, as measured by the ChIP assay, is related to the elevation of the gene in prostate cancer cells [45]. However, the mechanisms related to the increase in histone acetylation at the promoters of these mesenchymal markers remain unknown.

Histone acetylation in modulating the promoters of EMT-TFs
The EMT-TFs Snail, Twist, and ZEB, which are increased and activated early in the process of EMT, have been found to play central roles in the development of different cancers [3]. Importantly, recent studies have shown that the elevation of EMT-TFs mediated by histone acetylation with stimulation by different cellular factors, has beneficial effects on EMT. The roles of histone acetylation and the associated molecular mechanisms of EMT regulation by EMT TFs are described below.

Snail1 and Snail2
As two core EMT-TFs, Snail1 and Snail2 are increased and activated early and sufficiently to initiate EMT [13, 27]. The histone H3 acetylation of the Snail1 promoter is associated with the regulation of Snail1 expression. Moreover, based on ChIP-qPCR analysis, the recruitment of P300 mediated by DOT1L was found to be related to acetylation of H3 at its promoter in breast cancer cells [46]. Notably, histone acetylation at the promoters of Snail2 plays an essential role in its expression to accelerate EMT. For instance, increased histone H3 acetylation is related to elevated Snail2 expression in breast cancer cells [47]. Among the KATs, both GCN5 and P300 have been shown to contribute to histone H3K9, H3K14, and H3K18 acetylation at the Snail2 promoter, as examined by ChIP analysis. However, loss-of-function of SND1 results in a reduced recruitment of GCN5 and P300 to the Snail2 promoter, leading to a reduction in H3K9, H3K14, and H3K18 acetylation at its promoter to inhibit EMT in ovarian cancer cells [48]. Among KDACs, HDAC1 and HDAC3 suppress Snail2 expression by inhibiting histone acetylation at its promoter. For example, based on ChIP-seq and ChIP analyses, Mishra et al. found that the transcription factor KLF10 occupying GC-rich sequences at the promoter of Snail2 could repress Snail2 transcription by recruiting HDAC1, which blocked the acetylation of H3K9 and H3K27 at the promoter of Snail2 in lung adenocarcinoma cells [49]. In addition, during TGF-β-initiated EMT, the effect of TGF-β on Snail2 expression is related to the inhibition of HDAC1 and HDAC3, which can suppress Snail2 transcription by downregulating the acetylation levels of H3K56 and H3K4 in hepatocellular carcinoma (HCC) cells [50].

Hypoxia is a major environmental factor that induces gene reprogramming and initiates EMT. Under hypoxia, IncRNA RP11-367G18.1 plays an essential role in the elevation of H4K16 acetylation at the Snail2 promoter to enhance its expression in head and neck cancer cells (Table 1) [51].

Twist1 and Twist2
Up to now, Twist1 also has been reported to be regulated by histone acetylation. In particular, based on the ChIP assay, hypoxia was found to induce the polyubiquitination of HAUSP, which stabilizes HIF-1α and then causes H3K56 acetylation at the promoter of Twist1 to accelerate EMT, while H3K56 acetylation mediated by CBP contributes to the elevation of Twist1 transcription in multiple cancer cells [52]. In addition, EMT induced by Wnt/β-catenin and PI3-K signaling is correlated with the acetylation of H3K27 at the Twist1 promoter in gastric cancer cells [53]. IncRNA RP11-367G18.1, induced by hypoxia, also increases the acetylation of H4K16 located on the promoter of Twist1 to facilitate its expression and activation [51]. In addition to Twist1, elevated Twist2 expression was also found to be associated with an increased acetylation of H3 at the Twist2 promoter in HCC cells. Furthermore, the H3 acetylation of its promoter can be inhibited by ACOT12 [54]. Interestingly,
the role of ACOT12 in the decrease of H3 acetylation at the Twist2 promoter, detected by the ChIP assay, can be abolished by GCN5 (Table 1).

**ZEB1 and ZEB2**

ZEB1 has also been reported to be modulated by histone acetylation, contributing to EMT activation. Su et al. showed that MEF2D directly regulates ZEB1 transcription by promoting histone H3 and H4 acetylation at its promoter to facilitate EMT. With respect to molecular mechanisms, MEF2D significantly increases P300-binding to the promoter of ZEB1, and P300 may account for the upregulation of histone acetylation at the ZEB1 promoter in colorectal cancer cells [55]. In addition to ZEB1, increased H3 acetylation is related to increased ZEB2 gene expression in prostate cancer [45]. Moreover, Cho et al. showed that, depending on Co-IP and ChIP analysis, DOT1L cooperates with the c-Myc-P300 complex and initiates histone H3 acetylation at promoters of ZEB1 and ZEB2 (Table 1). Meanwhile, the protein complex results in the dissociation of HDAC1 from the promoters of these genes in breast cancer cells [46].

**Histone acetylation in modulating the promoters of EMT-related LncRNA**

As mentioned above, lncRNAs play vital roles in EMT activation. Among the molecular mechanisms associated with the regulation of lncRNA, the increased acetylation of histones at the lncRNA promoters facilitates the upregulation of lncRNA to trigger EMT. For example, elevated H3K27 acetylation at the promoter of lncRNA GHET1 (gene gastric carcinoma highly expressed transcript 1) activates its expression to enhance EMT in HCC cells [56]. Using quantitative reverse transcription PCR (RT-qPCR), the UCSC Genome Browser, and ChIP assays, the expression of lncRNA-ROR was found to be upregulated by the acetylation of histone H3K27 to induce EMT in retinoblastoma cells, and elevated H3K27 acetylation at the lncRNA-ROR promoter was associated with CBP [57]. The expression levels of lncRNA terminal differentiation-induced non-coding RNA (TINCR) significantly increased in trastuzumab-resistant breast cancer cells. The activation of TINCR by H3K27 acetylation positively modulated EMT in breast cancer cells. In addition, H3K27 acetylation in the promoter region of TINCR mediated by CBP has been found to be related to the upregulation of TINCR [58]. Chen et al. showed that LncRNA PLAC2 (placenta-specific protein 2) was upregulated in both oral squamous cell carcinoma cell lines and primary tissue samples. Enriched H3K27 acetylation at the PLAC2 promoter facilitates EMT in oral squamous cell carcinoma. Furthermore, based on ChIP experiments, CBP was shown to increase the acetylation levels of H3K27 at the PLAC2 promoter, thereby upregulating PLAC2 [59]. The lncRNA ANCR has also been found to play vital roles in EMT regulation and tumor metastasis in many tumors. Wen et al. reported that elevated H3/H4 histone acetylation at the ANCR promoter is related to an increase of the lncRNA. Moreover, blocking HDAC3 can increase ANCR expression in HCC cells [32]. Current evidence shows that many lncRNAs participate in the regulation of EMT in different cancers [60–62]. However, the effect of histone acetylation on the regulation of these lncRNAs remains largely unknown.

**Contribution of non-histone acetylation to EMT regulation**

Although histones have been extensively reported to regulate gene transcription to control EMT, recent findings indicate that non-histone proteins could also be frequently acetylated [22, 24]. Moreover, acetylation can affect the subcellular localization, stability, and enzymatic activity of non-histone proteins [24]. To date, the regulation of the acetylation of EMT marker proteins, EMT-TFs, and signal transduction molecules in multiple signaling pathways related to EMT has been investigated (Fig. 1).

**Non-histone acetylation in modulating EMT marker proteins**

Among EMT-related epithelioid markers, E-cadherin is mainly located on the cell surface and is downregulated during EMT. To date, the nuclear localization of E-cadherin has been observed in various types of cancer. However, no information regarding its function in nuclear translocation has been reported. Zhao et al. showed that E-cadherin in the nucleus can be acetylated by CBP at K870 and K871 at the binding domain of the β-catenin promoter, while the acetylation of E-cadherin was reversed by SIRT2 (Fig. 1). Functionally, E-cadherin acetylation attenuates its interaction with β-catenin promoters, increasing downstream gene expression and accelerating EMT in cancer cells [63]. In addition to E-cadherin, vimentin, another EMT marker, is acetylated to facilitate its expression in HCC cells. In addition, SIRT5 binds to vimentin and deacetylates it at K120 in HCC cells [64]. However, whether other epithelioid and mesenchymal markers that are responsible for EMT could be regulated by non-histone acetylation has not been reported to date.

**Non-histone acetylation in modulating EMT-TFs**

As described above, an increase in histone acetylation at the promoters of EMT-TFs facilitates their expression and initiates EMT. Interestingly, emerging evidence demonstrates that the acetylation of core EMT-TFs, including
Snail, Twist, and ZEB, also contributes to EMT in different cancers [21]. In particular, multiple KATs and KDACs have been found to acetylate EMT TFs to regulate EMT (Fig. 1).

Snail1 and Snail2
Recent studies from different groups have reported that Snail1 can be acetylated to regulate its function [65–67]. In particular, based on Co-IP and mass spectrometry (MS) analysis, CBP was found to acetylate K146 and K187 of Snail1 to enhance its target gene expression in many cancer cells [68]. P300 acetylates Snail1 at K187 to facilitate its transcription in lung cancer (Fig. 1) [69]. Moreover, Snail1 acetylation contributes to the reduction of ubiquitylation, enhancing its stability [67]. As for Snail2, it has been found that the acetylation of this protein could promote its expression [70], and a study by Dai et al. showed that CBP interacts with Snail2, as detected by Co-IP assay, leading to the acetylation of Snail2 at K166 and K211. Additionally, Snail2 acetylation mediated by CBP can stabilize Snail2 and promote EMT in breast cancer [71]. However, Zhou et al. indicated that Snail2 undergoes acetylation-dependent protein degradation, and SIRT2 deacetylates Snail2 at K116 to prevent Snail2 degradation and extend Snail2 stability in breast cancer cells [72]. The reasons for the inconsistent role of Snail2 acetylation at different lysine residues assessed by different groups in breast cancer cells are not clear. Thus, further investigations are needed to explore the exact effect of Snail2 acetylation at different lysine residues on EMT.

Twist1 and Twist2
Twist1 is acetylated by PCAF, and Twist1 acetylation promotes its nuclear localization and transcriptional potential to initiate tumorigenesis. Moreover, K73, K76, and
K77 in Twist1 in bladder cancer cells [73]. Twist1 is also acetylated by Tip60 at K73 and K76 in basal-like breast cancers (Fig. 1) [74]. However, whether Twist2 can be acetylated remains unclear.

**ZEB1 and ZEB2**

ZEB1 and ZEB2 are capable of binding to regulatory gene sequences to repress or activate transcription. Interestingly, PCAF and P300 interact with ZEB1 to switch the protein from a transcriptional repressor to a transcriptional activator [13]. Furthermore, based on Co-IP assay, Mizuguchi et al. found that P300 and PCAF interact and form a complex with ZEB1, leading to its acetylation (Fig. 1). Moreover, acetylated ZEB1 increases miR-200c/141 transcriptional activity to facilitate EMT [75]. However, acetylation sites in ZEB1 were identified by Mizuguchi et al. Until now, whether acetylation affects the function of ZEB2 is not been well-defined.

**Non-histone acetylation in modulating other transcription factors**

In addition to established EMT-TFs, other transcription factors have also been shown to regulate EMT. However, the effects of different acetylated transcription factors on the EMT are diverse. For example, transcription factor KLF15 participates in EMT. The acetylation of KLF5 at K369 through P300 that induced by TGF-β maintains EMT and causes the metastasis of prostate cancer cells [76]. Although the acetylated transcription factor YY1 participates in EMT, SIRT1 can inhibit EMT in renal tubular cells by inhibiting YY1 acetylation in diabetic nephropathy [77]. Acetylated ISX and BRD4 are also involved in EMT. Moreover, based on MS analysis, PCAF was found to mediate ISX acetylation at K69 and BRD4 acetylation at K332 to facilitate EMT [78]. In addition, P300 was found to control EMT via the c-Myb acetylation at K471, K480, and K485 (Fig. 1) [79]. As mentioned above, α-SMA is an EMT-related mesenchymal marker. Ding et al. found that acetylated C/EBPβ can interact with the αSMA promoter and facilitate TGF-β-induced transcription of αSMA [80]. SIRT1 reverses C/EBPβ acetylation. Deacetylated C/EBPβ reverses elevated α-SMA expression. However, the acetylation sites of C/EBPβ have not been reported.

In contrast, GATA3 is a limiting factor in EMT. GATA3 acetylation at K119 mediated by CBP contributes to the inhibition of EMT, indicating that the deacetylation of GATA3 has a promotional effect on EMT in lung adenocarcinoma. However, HDAC1, HDAC2 and HDAC3 can deacetylate GATA3 [81]. As a subunit of the transcription factor AP-1, c-Jun, especially deacetylated c-Jun, contributes to the EMT. However, the downregulation of HDAC3 inhibits EMT in cutaneous squamous cell carcinoma by promoting c-Jun acetylation [82]. HIF-1α is also a regulator of EMT, and the deacetylation of HIF-1α, but not its acetylation, benefits EMT. Moreover, dependent on HDAC4, 14-3-3ζ was found to upregulate the expression of HIF-1α by promoting its deacetylation, which was detected by co-IP assays to facilitate EMT in HCC [83]. However, the acetylation sites of HIF-1α have not been identified. Zhu et al. also found that MTA2 enhances HIF-1α stability via deacetylation by interacting with HDAC1 to further activate HIF-1α transcriptional activity (Fig. 1) [84]. SIRT1 has been shown to have an inhibitory effect on EMT in ovarian cancer cells, with its inhibition of EMT being found to be related to the upregulation of CLDN5, an epithelial marker. Zhang et al. also found that SIRT1 could deacetylate the transcription factor KLF4 to activate CLDN5 transcription and inhibit EMT [85]. However, the deacetylation sites in KLF4 that are regulated by SIRT1 remain unknown. Together, these studies show that deacetylation of certain transcription factors also benefits EMT.

**Non-histone acetylation in modulating signal transduction molecules in different signaling pathways to facilitate EMT**

As described in the introduction, multiple signaling pathways participate in the initiation of EMT. Current evidence indicates that acetylation of the core signal transduction molecules is responsible for the activation of these target signaling pathways and the subsequent induction of EMT. To date, many signal transduction molecules in the TGF-β/Smad, NF-κB, JAK/STAT, and PI3-K signaling pathways have been acetylated (Fig. 1). In addition, the acetylation or deacetylation of these signal transduction molecules plays an essential role in the activation of different signaling pathways to induce EMT.

**TGF-β/Smad signaling pathway**

The activation of the TGF-β/Smad signaling pathway mediated by TGF-β family receptors plays a critical role in the induction of EMT [4]. Previous studies have focused on the regulation of EMT by the acetylation of important signal transduction molecules in this signaling pathway. In particular, based on Co-IP assay, TGF-β1-mediated EMT has been shown to be associated with Smad2, Smad3, and Smad4 acetylation (Fig. 1) [86, 87]. TGF-β2 promotes EMT by supporting Smad2 acetylation [88]. More importantly, among KATs and KDACs, P300/CBP mediates EMT by acetylating Smad2 and Smad3 [86]. However, SIRT6 inhibits the acetylation of Smad3 [89]. In addition, SIRT1, as well as SIRT7 can lead to an increase in the deacetylation of Smad4 [87, 90]. However, the acetylation sites of different Smad molecules have not been identified.
NF-κB signaling pathway
Current evidence has demonstrated that increased acetylation of p65 is responsible for NF-κB activation, which also facilitates EMT. For example, Huang et al. showed that trichostatin A (TSA) can promote EMT in esophageal squamous cell carcinoma by inducing the acetylation of p65 at K310 [91]. In addition, the interaction of p65 with P300 facilitates p65 acetylation, as detected by Co-IP experiments, which in turn interacts with the promoter of ZEB1, resulting in a decrease in E-cadherin [92]. However, Astragaloside IV inhibited glucose-induced EMT in podocytes by decreasing p65 acetylation. Similarly, SIRT1 contributes to p65 deacetylation in glucose-induced podocyte EMT, whereas OPN can inhibit SIRT1 expression and promote p65 acetylation in non-small cell lung cancer cells. Conversely, the overexpression of SIRT1 can restrict p65 acetylation, activation, and EMT [93, 94]. In addition, N-Myc-interacting protein (NMI) is capable of promoting the interaction of p65 with HDAC1, HDAC2, and HDAC3 and negatively regulates EMT by inhibiting p65 acetylation (Fig. 1) [95]. Except for p65, this signaling pathway is composed of a variety of signal transduction molecules, including IκB-α, IκB-β, IKKα, and IKKβ [96]. However, the information on the acetylation of these signal transduction molecules is not available.

JAK/STAT signaling pathway
The activation of the JAK/STAT signaling pathway mediated by cytokine receptors has also been shown to participate in EMT [3, 4]. In particular, STAT3 acetylation induced by IL-6 is required for EMT in CRC cells [97]. P300-dependent STAT3 acetylation, examined by the Co-IP assay, is necessary for EMT in renal tubular epithelial cells (Fig. 1) [98]. In addition, nicotinamide adenine dinucleotide (NAD) is known to have a significant effect on all aspects of human life. However, decreased NAD levels induce STAT3 acetylation to facilitate its activation [99]. Until now, the acetylation sites in STAT3 that are modulated by different factors in various cell types have not been well identified. To date, it remains unclear whether other signal transduction molecules in the JAK/STAT signaling pathway, including JAK1, JAK2, STAT1, and STAT2, can be acetylated and participate in EMT.

PI3-K signaling pathway
The activation of the PI3-K signaling pathway, which is stimulated by receptor tyrosine kinases, contributes to sensitization of the NF-κB signaling pathway to facilitate EMT [4]. AKT1 is a core signal transduction molecule in the PI3-K pathway, and its activation is dependent on phosphorylation. An et al. showed that HDAC8 can bind to AKT1 to decrease its acetylation while increasing its phosphorylation (Fig. 1). A detailed investigation based on MS suggested that K426 in the AKT protein is the key amino acid residue for the HDAC8-modulated deacetylation of this protein. Moreover, deacetylated AKT stabilizes Snail1 and activates EMT in breast cancer cells [100].

Targeting protein acetylation or deacetylation as a potential strategy to restrict EMT
Because lysine acetylation or deacetylation relies on KATs and KDACs, and up to now, a variety of small molecule inhibitors have been developed to suppress the catalytic reaction of KATs or KDACs, resulting in the hyperacetylation or deacetylation of histones or non-histone proteins [25, 101]. Our review suggests that the acetylation of histones and non-histone proteins facilitates EMT. In addition, the deacetylation of certain transcription factors and signal transduction molecules also contributes to EMT. Therefore, it is not surprising that KAT and KDAC inhibitors can suppress EMT.

To date, few KAT inhibitors have been investigated for EMT inhibition (Table 2). Current studies show that anacardic acid, a major constituent of cashew nutshells, is a non-selective KAT inhibitor [102, 103], and garcinol, a polyisoprenylated benzophenone derivative, mainly targets P300 [104] and ICG-001, a small molecule that inhibits CBP/β-catenin [105]. EGCG, a polyphenolic component from the green tea, is an inhibitor with the ability to suppress P300/CBP activity, blocking EMT in different cancer cells [86, 106]. In the future, further KAT inhibitors will need to be evaluated to determine their precise roles in the restriction of EMT in various cancer cells.

Several HDAC inhibitors, including belinostat, vorinostat, and panobinostat, have been approved for the treatment of cancers [25]. Furthermore, different clinical trials assessing the role of HDAC inhibitors in cancer treatment are underway [25]. More importantly, studies from different research groups indicate that the effect of HDAC inhibitors on the inhibition of various cancer cells is mainly mediated by targeting EMT (Table 2). For example, mocetinostat, a type of benzamide, is a class I HDAC inhibitor [107], while suberoylanilide hydroxamic acid (SAHA) and TSA, a type of hydroxamic acid [106, 108–111], are class I, II, and IV HDAC inhibitors. Valproic acid (VPA) and sodium butyrate, two types of short-chain fatty acids [112–120], are class I and II HDAC inhibitors, while MS-275, a type of benzamide, [121–123], is a class I HDAC inhibitor, and LBH589, a hydroxamic acid derivative, is a pan-KDAC inhibitor [124–128]. These have all been identified to suppress EMT in different cancer cells.

To date, the exact molecular mechanisms that contribute to the inhibition of EMT mediated by these HDAC inhibitors remain unclear. However, a growing body of evidence suggests that acetylation and deacetylation of histone and non-histone proteins are important for EMT. Therefore, the potential of HDAC inhibitors as therapeutic agents for the treatment of cancer cells is promising.
HDAC inhibitors have yet to be well defined. Among these HDAC inhibitors, TSA [129], SAHA [45, 70, 130, 131], and VPA have been shown to facilitate EMT in various cancer cells [66, 132–135]. The reasons for these contradictory conclusions regarding the effects of these three HDAC inhibitors on EMT remain unclear. Molecular factors involved in EMT are key targets for the development of new therapeutic strategies for tumor suppression. As mentioned above, many factors, including EMT-TFs, EMT-related lncRNAs, and EMT-related signaling pathways, are involved in the regulation of EMT. However, to date, the exact molecular targets of different HDAC inhibitors in various tumor types remain largely unknown. Therefore, further studies are needed to confirm the precise targets and detailed mechanisms of the effects of HDAC inhibitors on EMT in various types of cancers.

**Conclusions**

In summary, as a complex biological trans-differentiation process, EMT not only contributes to metastasis and invasion but also induces cell stemness and drug resistance in various cancers. In addition to EMT, partial EMT or hybrid E/M states are also present in tumors [9, 10]. Accumulating evidence indicates that tumor progression and metastasis are favored by tumor cells in partial EMT or hybrid E/M states [10]. It should be noted that despite our understanding of the role and mechanisms related to EMT, partial EMT, or hybrid E/M states in cancer progression is growing, much still remains to be elucidated. As mentioned above [15, 18, 19, 21], EMT could be regulated by epigenetic modulation and PTM. Drugs that influence epigenetic factors, including DNA methylation and histone modification, or target different types of PTMs, such as ubiquitylation, phosphorylation, and sumoylation, are potential therapeutic approaches for overcoming EMT. However, the molecular mechanisms underlying the epigenetic and post-translational mechanisms that modulate EMT are complex. Thus, to better target EMT in clinical treatment, a more thorough understanding of the cellular factors involved in epigenetic modulation and PTM is required.

Our review indicates that histones and non-histone proteins related to EMT can be acetylated. However, the effects of acetylation on these two proteins are diverse. Histone acetylation is an important epigenetic regulator, whereas non-histone protein acetylation is a critical PTM. Therefore, a better understanding of both the histone acetylation and non-histone acetylation of EMT-related cellular factors is important to develop a workable strategy to delete cells that have undergone EMT in cancer treatment. EMT-TFs, including Snail, Twist, and ZEB, are activated early to initiate EMT. Because of their vital role in modulating the EMT process, inhibiting their expression may be a highly effective way to reverse this process. In addition, many EMT-related signaling pathways, such as the TGF-β/Smad, NF-κB, JAK/STAT, and PI3-K signaling

| Drug name | Drug types | KAT or HDAC specificity | Target cancer cells | The role on EMT | References |
|-----------|------------|-------------------------|---------------------|----------------|-----------|
| Anacardic acid | KAT inhibitor | Non-selective KAT inhibitor | Breast cancer, Prostate cancer | Inhibit | [102, 103] |
| Garcinol | KAT inhibitor | P300 inhibitor | Breast cancer | Inhibit | [104] |
| EGCG | KAT inhibitor | P300/CBP inhibitor | Lung cancer | Inhibit | [86, 106] |
| ICG-001 | KAT inhibitor | CBP/β-catenin inhibitor | Nasopharyngeal carcinoma | Inhibit | [105] |
| Mocetinostat | HDAC inhibitor | class I KADC inhibitor | Pancreatic cancer, Lung cancer | Inhibit | [106] |
| SAHA | HDAC inhibitor | class I, II and IV, KADC inhibitor | Head and neck cancer, Triple-negative breast cancer, Breast mesenchymal cancer | Inhibit | [106–109] |
| TSA | HDAC inhibitor | class I, II and IV, KADC inhibitor | Breast cancer, Lung cancer | Inhibit | [110, 111] |
| Sodium butyrate | HDAC inhibitor | Class I, II and KADC inhibitor | HCC, Colorectal cancer, Bladder cancer | Inhibit | [112–114] |
| VPA | HDAC inhibitor | Class I, II KADC inhibitor | Gastric Cancer, HCC, Prostate carcinoma, Renal cell carcinoma, Esophageal squamous cell carcinoma, Prostate carcinoma | Inhibit | [115–120] |
| MS-275 | HDAC inhibitor | Class I KADC inhibitor | Breast cancer, Non-small cell lung cancer | Inhibit | [121–123] |
| LBHS89 | HDAC inhibitor | pan-KADC inhibitor | Colorectal cancer, Breast cancer, Prostate cancer, HCC | Inhibit | [124–128] |
| TSA | HDAC inhibitor | class I, II and IV, KADC inhibitor | Esophageal squamous | Activate | [129] |
| SAHA | HDAC inhibitor | class I, II and IV, KADC inhibitor | Prostate cancer, Lung cancer, Gastric cancer, Triple negative Breast cancer | Activate | [45, 70, 130, 131] |
| VPA | HDAC inhibitor | Class I, II KADC inhibitor | Colorectal cancer, Triple negative breast cancer, Breast cancer, HCC, Colon carcinoma | Activate | [66, 132–135] |
pathways, are known to contribute to the production of the EMT phenotype; therefore, inhibitors of these pathways need to be developed to overcome EMT. Our review of the literature shows that the expression and activation of these transcription factors and signaling pathways can be modulated by histone or non-histone protein acetylation. These findings imply that targeting histone or non-histone protein acetylation is an ideal strategy for controlling these transcription factors and signaling pathways, thereby inhibiting EMT.

More importantly, the acetylation of histone or non-histone proteins is controlled by KATs, and accumulating evidence indicates that KAT inhibitors can effectively inhibit EMT. However, the molecular targets mediated by KAT inhibitors that facilitate EMT suppression have not been fully investigated. In addition to acetylation, the evidence presented here shows that the histone deacetylation of EMT-related epithelioid markers and the non-histone deacetylation of certain transcription factors and signal transduction molecules also contribute to EMT. The deacetylation of histone and non-histone proteins is mainly controlled by KADCs, and the use of KADC inhibitors may provide an effective treatment strategy for EMT. Therefore, further identification of the specific functions and exact mechanisms of histone and non-histone protein acetylation and deacetylation linked to EMT mediated by KATs or KADCs may provide a unique opportunity to target the EMT-associated cancer progression.

Abbreviations
EMT: Epithelial-mesenchymal transition; KATs: Lysine acetyltransferases; KADCs: Lysine deacetylases; EMT-TFs: EMT-inducing transcription factors; PTMs: Post-translational modifications; HATs: Histone acetyltransferases; HDACs: Histone deacetylases; CPEBD: N-terminal truncated carboxypeptidase E; LncRNA: Long non-coding RNA; HCC: Hepatocellular carcinoma; GHT1: Gene gastric carcinoma high expressed transcript 1; TINCR: Terminal differentiation-induced non-coding RNA; PLAC2: Placenta-specific protein 2; SAHA: Suberoylanilide hydroxamic acid; VPA: Valproic acid; TSA: Trichostatin A.

Acknowledgements
The figures used in the study were created using BioRender (https://biorender.com/).

Author contributions
FK, LM, and XW drafted and wrote the manuscript and designed the artwork. HY, KZ, and RT supervised and revised the manuscript. All authors read and approved the final manuscript.

Funding
The work was supported by a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), and Xuzhou Technology Bureau Foundation (KC21065).

Availability of data and materials
Not applicable.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no conflict of interest.

Author details
1 Jiangsu Key Laboratory of Immunity and Metabolism, Department of Patho-genic Biology and Immunology, Xuzhou Medical University, Xuzhou, Jiangsu, China. 2 National Demonstration Center for Experimental Basic Medical Sciences Education, Xuzhou Medical University, Xuzhou, Jiangsu, China.

Received: 13 January 2022   Accepted: 20 March 2022

Published online: 28 April 2022

References
1. Debnath P, Huiirim RS, Dutta P, Palchaudhuri S. Epithelial-mesenchymal transition and its transcription factors. Biosci Rep. 2022;42:20211754.
2. Jia D, Park JH, Kaur H, Jung KH, Yang S, Tripathi S, et al. Towards decoding the coupled decision-making of metabolism and epithelial-to-mesenchymal transition in cancer. Br J Cancer. 2021;124:1902–11.
3. Jayachandran J, Srinivasan H, Mani KP. Molecular mechanism involved in epithelial to mesenchymal transition. Arch Biochem Biophys. 2021;710:108984.
4. Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20:669–84.
5. Ge X, Yao Y, Li J, Li Z, Han X. Role of LncRNAs in the epithelial-mesenchymal transition in hepatocellular carcinoma. Front Oncol. 2021;11:690800.
6. Borne L, Bethler G, van Rheenen J. Epithelial-to-mesenchymal transition in the light of plasticity and hybrid E/M states. J Clin Med. 2021;10:2403.
7. Gires O, Pan M, Schinke H, Canis M, Baueurle PA. Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years? Cancer Metastasis Rev. 2020;39:969–87.
8. Nieto MA, Huang RV, Jackson RA, Thiery JP. Emt: 2016. Cell. 2016;166:21–45.
9. Graziani V, Rodriguez-Hernandez I, Miques O, Sanz-Moreno V. The amoeboid state as part of the epithelial-to-mesenchymal transition programme. Trends Cell Biol. 2022;32:226–42.
10. Godin L, Balsat C, Van Eycke YR, Allard J, Royer C, Remmelink M, et al. A novel approach for quantifying cancer cells showing hybrid epithelial/mesenchymal states in large series of tissue samples: towards a new prognostic marker. Cancers (Basel). 2020;12:906.
11. Bronsert P, Enderle-Ammour K, Bader M, Timme S, Kuhes M, Csanadi A, et al. Cancer cell invasion and EMT marker expression: a three-dimensional study of the human cancer-host interface. J Pathol. 2014;234:410–22.
12. Celia-Terrassa T, Jolly MK. Cancer stem cells and epithelial-to-mesenchymal transition in cancer metastasis. Cold Spring Harb Perspect Med. 2020;10:036905.
13. Lamouille S, Xu J, Derynick R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–96.
14. Chen HT, Liu H, Mao MJ, Tan Y, Mo XQ, Meng XJ, et al. Crosstalk between autophagy and epithelial-mesenchymal transition and its application in cancer therapy. Mol Cancer. 2019;18:101.
15. Serresi M, Kertalli S, Li L, Schmitt MJ, Dramaretska Y, Wierikx J, et al. Functional antagonism of chromatin modulators regulates epithelial-mesenchymal transition. Sci Adv. 2021;7:7974.
16. Johnson KS, Hussein S, Chakraborty P, Muruganathan A, Mikhail S, Gonzalez G, et al. CTCF expression and dynamic motif accessibility

Kong et al. Cell Communication and Signaling (2022) 20:57  Page 11 of 14
modulates epithelial-mesenchymal gene expression. Cancers (Basel). 2022;14:209.

17. Lindner P, Paul S, Eckstein M, Hampel C, Muenzner JK, Erbenbach-Wuerisch K, et al. EMT transcription factor ZEB1 alters the epithogenic landscape of colorectal cancer cells. Cell Death Dis. 2020;11:1147.

18. Trager MM, Dhayat SA. Epigenetics of epithelial-to-mesenchymal transition in pancreatic carcinoma. Int J Cancer. 2017;141:24–32.

19. Shang BQ, Li ML, Quan HY, Hou PF, Li ZW, Chu SF, et al. Functional roles of circular RNAs during epithelial-to-mesenchymal transition. Mol Cancer. 2019;18:138.

20. Jia W, Deshmukh A, Mani SA, Jolly MK, Levine H. A possible role for epigenetic feedback regulation in the dynamics of the epithelial-mesenchymal transition (EMT). Phys Biol. 2019;16:066004.

21. Kang E, Seo J, Yoon H, Cho S. The post-translational regulation of epithelial-mesenchymal transition-inducing transcription factors in cancer metastasis. Int J Mol Sci. 2021;22:3591.

22. Ali I, Conrad RJ, Verdin E, Ott M. Lysine acetylation goes global: from epigenetics to metabolism and therapeutics. Chem Rev. 2018;118:1216–52.

23. Verdin E, Ott M. 50 years of protein acetylation: from gene regulation to metabolism and beyond. Nat Rev Mol Cell Biol. 2015;16:258–64.

24. Narita T, Weinert BT, Choudhary C. Functions and mechanisms of non-histone protein acetylation. Nat Rev Mol Cell Biol. 2019;20:156–74.

25. Li P, Ge J, Li H. Lysine acetyltransferases and lysine deacetylases as targets for cardiovascular disease. Nat Rev Cardiol. 2020;17:96–115.

26. Menezes KJ, Zhang H, Katsyuba E, Auwerx J. Protein acetylation in metabolism–metabolites and cofactors. Nat Rev Endocrinol. 2016;12:43–60.

27. Dong B, Gu Z, Wu Y. Tackle epithelial-mesenchymal transition with epigenetic drugs in cancer. Front Pharmacol. 2020;11:596239.

28. Mobley RJ, Abell AN. Controlling epithelial to mesenchymal transition through acetylation of histone H2B.5K. J Nat Sci. 2017;3:9.

29. Abell AN, Jordan NV, Huang W, Prat A, Midland AA, Johnson NL, et al. MAP3K4/CBP-regulated H2B acetylation controls epithelial-mesenchymal transition in trophoblast stem cells. Cell Stem Cell. 2011;8:525–37.

30. Lin SH, Wang BY, Lin CH, Chien PJ, Wu YF, Ko JL, et al. Chidamide alleviates extracellular matrix stress and inhibits epithelial-mesenchymal transition in lung cancer cell lines. Mol Biol Rep. 2016;43:687–95.

31. Javaid S, Zhang J, Anderssen E, Black JC, Wittner BS, Tajima K, et al. Dynamic chromatin modification sustains epithelial-mesenchymal transition following inducible expression of Snail-1. Cell Rep. 2015;13:1679–89.

32. Wen Z, Liu L, Ding H, Hu Y, Xiao Z, Xiong K, et al. LncRNA ANCR promotes hepatocellular carcinoma metastasis through upregulating HNRNPA1 expression. RNA Biol. 2020;17:381–94.

33. Wang F, Zhang W, Song Z, Wang M, Wu H, Yang Y, et al. A novel miRNA inhibits metastasis of prostate cancer via decreasing CREBBP-mediated histone acetylation. J Cancer Res Clin Oncol. 2021;147:469–80.

34. Sun L, Kokura K, Iizumi V, Koomen JM, Seto E, Chen J, et al. MPP8 and HDACs modulate epithelial-mesenchymal transition. Phys Biol. 2019;16:066004.

35. Peinado H, Ballestar E, Esteller M, Cano A. Snail mediates E-cadherin suppression and metastasis in lung carcinoma facilitated by S6K1. J Cell Metab. 2019;20:1284372.

36. Kong D, Ahmad A, Bao B, Li Y, Banerjee S, Sarkar FH. Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells. PLoS ONE. 2012;7:e45045.

37. Cho MH, Park JH, Choi HJ, Park MK, Won HY, Park YJ, et al. DOT1L cooperates with the s-Myc-P300 complex to epigenetically represses CDH1 transcription factors in breast cancer progression. Nat Commun. 2015;6:7821.

38. Kamiya T, Goto A, Kurokawa E, Hara H, Adachi T. Cross talk mechanism among EMT, ROS, and histone acetylation in phorbol ester-treated human breast cancer MCF-7 cells. Oxid Med Cell Longev. 2016;2016:1284372.

39. Xin L, Zhao R, Lei J, Song J, Yu L, Gao R, et al. SNI1 acts upstream of SLUG to regulate the epithelial-to-mesenchymal transition (EMT) in SKOV3 cells. FASEB J. 2019;33:795–806.

40. Hu Y, Nie Q, Dai M, Chen F, Wu H. Histone deacetylases inhibit the Snail2-mediated EMT during metastasis of hepatocellular carcinoma cells. Front Cell Dev Biol. 2020;8:752.

41. Peng PH, Lai JC, Chang JS, Hue CW, Wu KJ. Induction of epithelial-mesenchymal transition (EMT) by hypoxia-induced lncRNA RP11–367G18.1 through regulating the histone 4 lysine 16 acetylation (H4K16Ac) mark. Am J Cancer Res. 2021;11:2618–36.

42. Wu HT, Kuo YC, Hung JJ, Huang CH, Chen WY, Chou TY, et al. K63-poly-ubiquitinated HAUSP deubiquitates HIF-1alpha and dictates H3K56 acetylation promoting hypoxia-induced tumour progression. Nat Commun. 2016;7:13644.

43. Song Y, Li ZX, Liu X, Wang R, Li LW, Zhang Q. The Wnt/beta-catenin and PI3K/Akt signaling pathways promote EMT in gastric cancer by epigenetic regulation via H3 lysine 27 acetylation. Tumour Biol. 2017;39:1010428317712617.

44. Lu M, Zhu WW, Wang X, Tang JJ, Zheng KL, Yu GY, et al. ACOT12-dependent alteration of acetyl-CoA drives hepatocellular carcinoma metastasis by epigenetic induction of epithelial-mesenchymal transition. Cell Metab. 2019;29:886–900.

45. Su L, Luo Y, Yang Z, Yang J, Yao C, Cheng F, et al. MEF2D transduces microenvironment stimuli to ZEB1 to promote epithelial-mesenchymal transition and metastasis in colorectal cancer. Cancer Res. 2016;76:5054–67.

46. Ding G, Li W, Liu J, Zeng Y, Mao C, Kang Y, et al. LncRNA GHT1 activated by H3K27 acetylation promotes cell tumorigenesis through regulating ATF1 in hepatocellular carcinoma. Biomed Pharmacother. 2017;94:326–31.

47. Gao Y, Luo X, Zhang J. LincRNA-ROR is activated by H3K27 acetylation and induces EMT in retinoblastoma by acting as a sponge of miR-32 to activate the Notch signaling pathway. Cancer Gene Ther. 2021;28:42–54.

48. Dong H, Hu J, Zou K, Ye M, Chen Y, Wu C, et al. Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer. Mol Cancer. 2019;18:3.
Kong et al. Cell Communication and Signaling  (2022) 20:57
Page 13 of 14

59. Chen F, Qi S, Zhang X, Wu J, Yang X, Wang R. IncRNA PLAC2 activated by H3K27 acetylation promotes cell proliferation and invasion via the activation of Wnt/betacatenin pathway in oral squamous cell carcinoma. Int J Oncol. 2019;54:1183–94.

60. Hamidi AA, Khalili-Tanha G, Naspour Navaee Z, Moghbeli M. Long non-coding RNAs as the critical regulators of epithelial mesenchymal transition in colorectal tumor cells: an overview. Cancer Cell Int. 2022;22:71.

61. Takahashi K, Tanie K, Ono Y, Fujiya M, Muzumaki Y, Okumura T. Long non-coding RNAs in epithelial-mesenchymal transition of pancreatic cancer. Front Mol Biosci. 2021;8:717965.

62. Zhang X, Chen X, Jin J, Lin X. Biological functions and clinical significance of long noncoding RNAs in bladder cancer. Cell Death Discov. 2021;7:278.

63. Zhao Y, Yu T, Zhang N, Chen J, Zhang P, Li S, et al. Nuclear E-cadherin acetylation promotes colorectal tumorigenesis via enhancing beta-catenin activity. Mol Cancer Res. 2019;17:655–65.

64. Guo D, Song K, Guo G, Gu S, Chang X, Su T, et al. Vimentin acetylation is involved in SIRT5-mediated hepatocellular carcinoma migration. Am J Cancer Res. 2018;8:2453–66.

65. Jiang GM, Wang HS, Zhang F, Zhang KS, Liu ZC, Fang R, et al. Histone deacetylase inhibitor induction of epithelial-mesenchymal transitions via up-regulation of Snail facilitates cancer progression. Biochim Biophys Acta. 2013;1833:663–71.

66. Feng J, Chen L, Li Z, Zhao R, Zhu C, Wang Z, et al. Histone deacetylase inhibitor valproic acid (VPA) promotes the epithelial mesenchymal transition of colorectal cancer cells via up regulation of Snail. Cell Adh Migr. 2015;9:495–501.

67. Xu W, Liu H, Liu ZG, Liu ZY, Wang HS, Zhang F, et al. Histone deacetylase inhibitors upregulate Snail via Smad2/3 phosphorylation and stabilization of Snail to promote metastasis of hepatoma cells. Cancer Lett. 2018;420:1–13.

68. Hsu DS, Wang HJ, Tai SK, Chou CH, Hsieh CH, Chiu PH, et al. Acetylation of snail modulates the cytokinome of cancer cells to enhance the recruitment of macrophages. Cancer Cell. 2014;26:534–48.

69. Chang R, Zhang Y, Zhang P, Zhou Q. Snail acetylation by histone acetyltransferase P300 in lung cancer. Thorac Cancer. 2017;8:131–7.

70. Wang J, Xu MQ, Jiang XL, Mei XY, Liu XG. Histone deacetylase inhibitor SAHA-induced epithelial-mesenchymal transition by upregulating Snug in lung cancer cells. Anticancer Drugs. 2018;29:80–8.

71. Dai X, Xin Y, Xu W, Tian X, Wei X, Zhang H. CBP-mediated Slug acetylation stabilizes Slug and promotes EMT and migration of breast cancer cells. Sci China Life Sci. 2021;64:563–74.

72. Zhou W, Ni TK, Wronski A, Glass B, Skibinski A, Beck A, et al. The SIRT2 deacetylase stabilizes slug to control malignancy of basal-like breast cancer. Cell Rep. 2016;17:1302–17.

73. Shiota M, Yokomizo A, Tada Y, Uchiumi T, Inokuchi J, Tatsugami K, et al. P300/CBP-associated factor regulates Y-box binding protein-1 expression and promotes cancer cell growth, cancer invasion and drug resistance. Cancer Sci. 2010;101:1797–806.

74. Wang LT, Wang SN, Chou SS, Liu KY, Chai CY, Chiang CM, et al. TIP60-dependent acetylation of the SP21-TWIST complex promotes epithelial-mesenchymal transition and metastasis in liver cancer. Oncogene. 2019;38:518–22.

75. Mizuguchi Y, Specht S, Lunz JG 3rd, Isse K, Corbitt N, Takizawa T, et al. Reciprocal loop of E-cadherin and Snail as the critical regulators of epithelial-mesenchymal transition in colorectal tumor cells: an overview. Cancer Cell Int. 2022;22:2207–19.

76. Tang Y, Liu S, Li N, Guo W, Shi J, Yu H, et al. 14-3-3zeta promotes hepatocellular carcinoma venous metastasis by modulating hypoxia-inducible factor-1alpha. Oncotarget. 2016;7:15854–67.

77. Zhu S, Deng S, He C, Liu M, Chen H, Zeng Z, et al. Reciprocal loop of hypoxia-inducible factor-1alpha (HIF-1alpha) and metastasis-associated protein 2 (MTA2) contributes to the progression of pancreatic cancer by suppressing E-cadherin transcription. J Pathol. 2018;245(3):349–60.

78. Zhang X, Chen J, Sun L, Xu Y. SIRT1 deacetylates KLF5 to activate Claudin-5 transcription in ovarian cancer cells. J Cell Biochem. 2018;119:2418–26.

79. Ko H, So Y, Jeon H, Jeong MH, Choi HK, Ryu SH, et al. TGF-beta1-induced epithelial-mesenchymal transition and acetylation of Smad2 and Smad3 are negatively regulated by EGC2 in human A549 lung cancer cells. Cancer Lett. 2013;335:205–13.

80. Chen IC, Chang WF, Huang HJ, Chen PF, Sheny YN, Chang HC. Role of SIRT1 in regulation of epithelial-mesenchymal transition in oral squamous cell carcinoma metastasis. Mol Cancer. 2014;13:254.

81. Corbet C, Bastien E, Santiago de Jesus JP, Dierge E, Martherus R, Vander Linden C, et al. TGFbeta2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells. Nat Commun. 2020;11:454.

82. Wang X, JT, Li X, Qu X, Bai S. FOXO3a protects against kidney injury in type II diabetic nephropathy by promoting sirtd3 expression and inhibiting Smad3 acetylation. Oxd Med Cell Longev. 2021;2021:5565761.

83. Li W, Zhu D, Qin S. SIRT7 suppresses the epithelial-to-mesenchymal transition in oral squamous cell carcinoma metastasis by promoting SMAD4 deacetylation. J Exp Clin Cancer Res. 2018;37:148.

84. Huang K, Liu Y, Gu C, Liu D, Zhao B. Tribosolin A augments esophageal squamous cell carcinoma cells migration by inducing acetylation of RelA at K310 leading epithelia-mesenchymal transition. Anticancer Drugs. 2020;31:567–74.

85. Hung JY, Chang SR, Tsai MJ, Tsai YM, Chong IW, Sheih JM, et al. LIGHT is a crucial mediator of airway remodeling. J Cell Physiol. 2015;230:1042–53.

86. Wang X, Gao Y, Tian N, Wang T, Shi Y, Xu J, et al. Astragalin decreases glucose-induced epithelial-mesenchymal transition of podocytes through autophagy enhancement via the SIRT1-NF-kappaB/p65 axis. Sci Rep. 2019;9:323.

87. Li X, Jiang Z, Zhang X. SIRT1 overexpression protects non-small cell lung cancer cells against osteopontin-overexpressed epithelial-mesenchymal transition by suppressing NF-kappaB signaling. Onco Targets Ther. 2018;11:1157–71.

88. Hou J, Wang T, Xie Q, Deng W, Yang JY, Zhang SQ, et al. N-Myc-interacting protein (NMI) negatively regulates epithelial-mesenchymal transition by inhibiting the acetylation of NF-kappaB/p65. Cancer Lett. 2016;376:22–33.

89. Zhang Q, Lenardo MJ, Baltimore D. Convergent relevance of tumor and normal physiology. Cell. 2017;168:37–57.

90. Liu H, Ren G, Wang T, Chen Y, Gong C, Bai Y, et al. Aberrantly expressed transcription factor-1alpha negatively regulates epithelial-mesenchymal transition. Carcinogenesis. 2015;36:459–68.

91. Li J, Shen Y, Wang Z, Shao DC, Liu J, Kong YL, et al. P300-dependent STAT3 acetylation is necessary for angiotensin II-induced pro-fibrotic responses in renal tubular epithelial cells. Acta Pharmacol Sin. 2014;35:1157–66.

92. Wang W, Hu Y, Yang C, Zhu S, Wang X, Zhang Z, et al. Decreased NAD+ activates STAT3 and integrin pathways to drive epithelial-mesenchymal transition. Mol Cell Proteom. 2018;17:2005–17.

93. An P, Chen F, Li Z, Zheng Y, Peng Y, Zhang H, et al. HDAC8 promotes the dissemination of breast cancer cells via AKT/GSK3beta/Snail signals. Oncogene. 2020;39:4956–69.
101. Kopyto P, Piotrowska K, Janisiak J, Tarnowski M. Garcinol-A natural histone deacetyltransferase inhibitor and new anti-cancer epigenetic drug. Int J Mol Sci. 2021;22:2828.

102. Shilpa P, Kaveri K, Salimath BP. Anti-metastatic action of anacardic acid targets VEGF-induced signalling pathways in epithelial to mesenchymal transition. Drug Discov Ther. 2015;9:53–65.

103. Fernandez HR, Linden SK. The aspirin metabolite salicylate inhibits lysine acetyltransferases and MUC1 induced epithelial to mesenchymal transition. Sci Rep. 2017;7:15626.

104. Ahmadi A, Sarkar SH, Bitar B, Ali S, Aboukameel A, Sethi S, et al. Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo, leading to anticancer activity against breast cancer cells. Mol Cancer Ther. 2012;11:2193–201.

105. Chan KC, Chan LS, Ip JC, Lo C, Yip TT, Ngan RK, et al. Therapeutic targeting of CBP/beta-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin. Sci Rep. 2015;5:9979.

106. Steed KL, Jordan HR, Tollefsbol TO. SAHA and EGCG promote apoptosis in triple-negative breast cancer cells, possibly through the modulation of cFLIP. Anticancer Res. 2020;40:9–26.

107. Meidhof S, Brabletz S, Lehmann W, Preca BT, Mock K, Ruh M, et al. ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Mol Biol. 2015;5:831–47.

108. Citro S, Bellini A, Miccolo C, Ghiari L, Carey TC, Chiocca S. Synergistic antitumour activity of HDAC inhibitor SAHA and EGFRII inhibitor gefitinib in head and neck cancer: a key role for DeltaNp63alpha. Br J Cancer. 2019;120:658–67.

109. Wawruszak A, Gumbarewicz E, Okon E, Jeleniewicz W, Czapinski J, Halska M, et al. Histone deacetylase inhibitors reinforce the phenotypically distinct markers of breast epithelial or mesenchymal cancer cells but inhibit their migratory properties. Cancer Manag Res. 2019;11:8345–58.

110. Wang X, Chen S, Shen T, Lu H, Xiao D, Zhao M, et al. Trichostatin A reverses epithelial-mesenchymal transition and attenuates invasion and migration in MCF-7 breast cancer cells. Exp Ther Med. 2020;19:1687–94.

111. Yao X, Ireland SK, Pham T, Temple B, Chen R, Jay MH, et al. TLE1 promotes EMT in AS49 lung cancer cells through suppression of E-cadherin. Biochim Biophys Res Commun. 2014;455:277–84.

112. Wang HG, Huang XD, Shen P, Lu L, Xue HT, Ji GZ. Anticancer effects of sodium butyrate on hepatocellular carcinoma cells in vitro. Int J Mol Med. 2013;31:967–74.

113. Wang W, Fang D, Zhang H, Xue J, Wangchuk D, Ju D, et al. Sodium butyrate selectively kills cancer cells and inhibits migration in colorectal cancer by targeting thoredoxin-1. Onco Targets Ther. 2020;13:4691–704.

114. Wang F, Wu H, Fan M, Yu R, Zhang Y, Liu J, et al. Sodium butyrate inhibits migration and induces AMPK-mTOR pathway-dependent autophagy and ROS-mediated apoptosis via the mTOR-S6K1/70S6K1-AKT-IHC pathway in human bladder cancer cells. FASEB J. 2020;34:4266–82.

115. Jahani M, Khanahmad H, Nikpour P, Evaluation of the effects of valproic acid treatment on cell survival and epithelial-mesenchymal transition-related features of human gastric cancer cells. J Gastrointest Cancer. 2021;52:676–81.

116. Liu J, Yang X, Liang Q, Yu Y, Shen X, Sun G. Valproic acid overcomes sorafenib resistance by reducing the migration of Jagged2-mediated Notch1 signaling pathway in hepatocellular carcinoma cells. Int J Biochem Cell Biol. 2020;126:105820.

117. Qi G, Lu G, Yu J, Zhao Y, Wang C, Zhang H, et al. Up-regulation of TGF-1gamma by valproic acid inhibits the epithelial mesenchymal transition in prostate cancer through TGF-beta/Smad signaling pathway. Eur J Pharmacol. 2019;860:172551.

118. Mao S, Lu G, Lai C, Jiang W, Chen Y, et al. Valproic acid inhibits epithelial-mesenchymal transition in renal cell carcinoma by decreasing SMAD4 expression. Mol Med Rep. 2017;16:6190–9.

119. Kanamoto A, Noinomyja I, Harada S, Tsukada T, Okamoto K, Nakamura S, et al. Valproic acid inhibits irradiation-induced epithelial-mesenchymal transition and stem cell-like characteristics in esophageal squamous cell carcinoma. Int J Oncol. 2016;49:1859–69.

120. Lan X, Lu G, Yuan C, Mao S, Jiang W, Chen Y, et al. Valproic acid (VPA) inhibits the epithelial-mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4. J Cancer Res Clin Oncol. 2016;142:177–85.

121. Shah P, Gau Y, Sabnis G. Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by repressing the repression of E-cadherin. Breast Cancer Res Treat. 2014;143:99–111.

122. Nagatohahalli NS, Massion PP, Gonzalez AL, Lu P, Datta PK. Smoking induces epithelial-to-mesenchymal transition in non-small cell lung cancer through HDAC-mediated downregulation of E-cadherin. Mol Cancer Ther. 2012;11:2362–72.

123. Srivastava RK, Kurzrock R, Shankar S. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther. 2010;9:3254–66.

124. Rhodes LV, Tate CR, Segar HC, Burks HE, Phamdy TB, Hocq V, et al. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Breast Cancer Res Treat. 2014;145:593–604.

125. Ling H, Kuo CC, Lin BX, Hsin YC, Lin CW. Elevation of YAP promotes the epithelial-mesenchymal transition and tumor aggressiveness in colorectal cancer. Exp Cell Res. 2017;350:218–25.

126. Ruscetti M, Dadashian EL, Guo W, Quach B, Mulholland DJ, Park JW, et al. HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastasis, castration-resistant prostate cancer. Oncogene. 2016;35:3781–95.

127. Jia F, Fizao P, Montalbano R, Quint K, Alinger B, Kemmerling R, Kiesslich T, et al. The pan-deacetylase inhibitor panobinostat modulates the expression of epithelial-mesenchymal transition markers in hepatocellular carcinoma models. Oncol Lett. 2013;5:127–34.

128. Song X, Wang J, Zheng T, Song R, Liang Y, Bhatta N, et al. LBH589 inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway. Mol Cancer. 2013;12:114.

129. Liu D, Liu Y, Qi B, Gu C, Huo S, Zhao B. Trichostatin A promotes esophageal squamous cell carcinoma cell migration and EMT through BRD4/ERK1/2-dependent pathway. Cancer Med. 2021;10:5235–45.

130. Yang S, He F, Dai M, Pan J, Wang J, Ye B. CHFR promotes the migration of human gastric cancer cells by inducing epithelial-to-mesenchymal transition in a HDAC1-dependent manner. Onco Targets Ther. 2019;12:1075–84.

131. Wu S, Luo Z, Yu PJ, Xie H, He YW. Suberoylanilide hydroxamic acid (SAHA) promotes the epithelial mesenchymal transition of triple negative breast cancer cells via HDAC8/FOXA1 signals. Biol Chem. 2016;397:75–83.

132. Ozman Z, Ozbek Ipect B, Sahin E, Guney Eskiler G, Deveci Ozkan A, Kaleli S. Regulation of valproic acid induced EMT by AKT/GSK3beta/beta-catenin signaling pathway in triple negative breast cancer. Mol Biol Rep. 2021;48:1335–43.

133. Zhang S, Tang S, Qian B, Tang R, Duan Q, Ding S, et al. Valproic acid promotes the epithelial-to-mesenchymal transition of breast cancer cells through stabilization of Snail and transcriptional upregulation of Zeb1. Eur J Pharmacol. 2019;865:172745.

134. Wu L, Feng H, Hu J, Tian X, Zhang C. Valproic acid (VPA) promotes the epithelial mesenchymal transition of hepatocarcinoma cells via transcriptional and post-transcriptional up regulation of Snail. Biomed Pharmacother. 2016;84:1029–35.

135. Ji M, Lee EJ, Kim KB, Kim Y, Sung R, Lee SJ, et al. HDAC inhibitors induce epithelial-mesenchymal transition in colon carcinoma cells. Oncol Rep. 2015;33:2299–308.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.